相似文献
1
Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.
Antimicrob Agents Chemother. 2004 Mar;48(3):1065. doi: 10.1128/AAC.48.3.1065.2004.
2
Successful management of postpneumonectomy Aspergillus pleural empyema by combined surgical and anti-fungal treatment with voriconazole and caspofungin.
Mycoses. 2010 Sep;53(5):448-54. doi: 10.1111/j.1439-0507.2009.01729.x. Epub 2009 May 29.
3
Microgranulomatous aspergillosis in a patient with chronic granulomatous disease: cure with voriconazole.
Clin Infect Dis. 1998 Apr;26(4):996-7. doi: 10.1086/517646.
4
Voriconazole. UK 109496.
Drugs R D. 1999 Feb;1(2):187-8. doi: 10.2165/00126839-199901020-00020.
5
Voriconazole for the treatment of refractory Aspergillus fumigatus keratitis.
Indian J Ophthalmol. 2008 May-Jun;56(3):243-5. doi: 10.4103/0301-4738.40369.
6
Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
Antimicrob Agents Chemother. 2005 Sep;49(9):3697-701. doi: 10.1128/AAC.49.9.3697-3701.2005.
7
A case of Aspergillus empyema successfully treated with combination therapy of voriconazole and micafungin: excellent penetration of voriconazole and micafungin into pleural fluid.
Intern Med. 2010;49(12):1163-9. doi: 10.2169/internalmedicine.49.2860. Epub 2010 Jun 15.
8
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.
Expert Rev Anti Infect Ther. 2013 Sep;11(9):931-41. doi: 10.1586/14787210.2013.826989.
9
Voriconazole concentrations in synovial fluid and bone tissues.
J Antimicrob Chemother. 2007 Apr;59(4):818-9. doi: 10.1093/jac/dkm023. Epub 2007 Feb 28.
10
The use of voriconazole in the treatment of Aspergillus fumigatus keratitis.
Br J Ophthalmol. 2007 Aug;91(8):1094-6. doi: 10.1136/bjo.2006.111989.
引用本文的文献
1
The outcomes of thoracoscopic decortication between fungal empyema and bacterial empyema.
BMC Infect Dis. 2023 Jan 6;23(1):8. doi: 10.1186/s12879-022-07978-z.
2
Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes.
Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa656. doi: 10.1093/ofid/ofaa656. eCollection 2021 Apr.
3
Pleural aspergillosis in a patient with recurrent spontaneous pneumothorax: The challenge of an optimal therapeutic approach.
Med Mycol Case Rep. 2020 Feb 24;28:4-7. doi: 10.1016/j.mmcr.2020.02.004. eCollection 2020 Jun.
4
Anidulafungin Pharmacokinetics in Ascites Fluid and Pleural Effusion of Critically Ill Patients.
Antimicrob Agents Chemother. 2018 Mar 27;62(4). doi: 10.1128/AAC.02326-17. Print 2018 Apr.
5
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12.
6
A 19-year-old woman with pleuritic chest pain.
Can J Infect Dis Med Microbiol. 2015 Mar-Apr;26(2):100-2. doi: 10.1155/2015/652758.
7
Pleural Aspergillosis in an otherwise healthy individual.
Lung India. 2014 Apr;31(2):155-7. doi: 10.4103/0970-2113.129851.
8
Tissue penetration of antifungal agents.
Clin Microbiol Rev. 2014 Jan;27(1):68-88. doi: 10.1128/CMR.00046-13.
9
Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.
Antimicrob Agents Chemother. 2011 May;55(5):2478-80. doi: 10.1128/AAC.01560-10. Epub 2011 Mar 14.
10
Human tissue distribution of voriconazole.
Antimicrob Agents Chemother. 2011 Feb;55(2):925-8. doi: 10.1128/AAC.00949-10. Epub 2010 Nov 15.
本文引用的文献
1
Voriconazole: a new triazole antifungal agent.
Ann Pharmacother. 2003 Mar;37(3):420-32. doi: 10.1345/aph.1C261.
2
Antibiotic levels in empyemic pleural fluid.
Chest. 2000 Jun;117(6):1734-9. doi: 10.1378/chest.117.6.1734.
3
Fungal empyema thoracis: an emerging clinical entity.
Chest. 2000 Jun;117(6):1672-8. doi: 10.1378/chest.117.6.1672.
Zotero 插件